One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-148385
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
Affiliation: Emory University, Mayo Clinic Hospital, Center for Cancer and Blood Disorders, Medical College of Wisconsin, Takeda (United States), Mayo Clinic, Indiana University – Purdue University Indianapolis, Cornell University, New York Hospital Queens, NewYork–Presbyterian Hospital, Dana-Farber Cancer Institute, Baylor University Medical Center, TriHealth, Nebraska Cancer Specialists, Texas OncologyPhase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
